title: Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection.
abstract: We investigated the potential of inducing additional T-cell immunity during chronic HIV-1 infection directed to subdominant HIV-1 epitopes from common HLA-supertypes. Ten treatment-naïve HIV-1-infected individuals were immunized with peptides in the adjuvant CAF01. One individual received placebo. T-cell immunogenicity was examined longitudinally by a flow cytometry (CD107a, IFNγ, TNFα, IL-2 and/or MIP1β expression) as well as IFNγ ELISPOT. Safety was evaluated by clinical follow up combined with monitoring of biochemistry, hematology, CD4 T-cell counts and viral load. New CD4 and CD8 T-cell responses specific for one or more vaccine epitopes were induced in 10/10 vaccinees. The responses were dominated by CD107a and MIP1β expression. There were no significant changes in HIV-1 viral load or CD4 T-cell counts. Our study demonstrates that the peptide/CAF01 vaccine is safe and that it is possible to generate new HIV-1 T-cell responses to defined epitopes in treatment-naïve HIV-1-infected individuals.
authors: Department of Virology, Statens Serum Institut, 2300 Copenhagen, Denmark.
authors: Ingrid
authors: I
authors: Karlsson
authors: Lea
authors: L
authors: Brandt
authors: Lasse
authors: L
authors: Vinner
authors: Ingrid
authors: I
authors: Kromann
authors: Lars Vibe
authors: LV
authors: Andreasen
authors: Peter
authors: P
authors: Andersen
authors: Jan
authors: J
authors: Gerstoft
authors: Gitte
authors: G
authors: Kronborg
authors: Anders
authors: A
authors: Fomsgaard
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000821:virology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000821:virology; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy*; D015234:HLA-A Antigens / Q000008:administration & dosage / Q000235:genetics; D015235:HLA-B Antigens / Q000008:administration & dosage / Q000235:genetics; D015236:HLA-C Antigens / Q000008:administration & dosage / Q000235:genetics; D006801:Humans; D016056:Immunodominant Epitopes / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D016037:Single-Blind Method; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D018984:Epitopes, T-Lymphocyte; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D015236:HLA-C Antigens; D016056:Immunodominant Epitopes; D010455:Peptides